"Our finding of a difference between miRNA expression in normal versus cancerous colon tissues should provide insight into mechanisms of colon cancer development and identify novel drugs to treat the disease" he said.
Expression Profiles of 16 Genes Predict Prostate Carcinoma Relapse and Disease Free Survival in Formalin-Fixed, Paraffin-Embedded (FFPE) Benign and Prostate Carcinoma Tissues Using Universal Bead Arrays: Abstract No. 1203
Researchers say that a chip that measures expression of 16 genes provides much needed prognostic information for prostate cancer patients who fall in the "gray zone" of traditional tests.
This experimental "universal bead array" test, which is designed to be low cost and easy to administer, appears to be a better predictor of relapse and disease-free survival than the Gleason Score, according to lead author Jessica Wang-Rodriguez, M.D., associate clinical professor of Pathology at the University of California, San Diego.
The 50 year-old Gleason Score, which assigns a progressive score of 1-10, based on how differentiated the cells look in a prostate cancer sample, works fairly well when the score is either very low or very high, but the prognosis for men who have scores in the mid-range is difficult to predict, Wang-Rodriguez said.
"It is very difficult to predict relapse and cancer recurrence in men who have a score of 6 or 7," she said. "Half of patients with these scores do well, and the other half don't, but we cannot now predict who will fall into those groups."
Believing that a gene microarray test might provide additional information, a team of researchers led by Wang-Rodriguez picked 512 genes from
Source:American Association for Cancer Research